U.S. patent application number 14/735588 was filed with the patent office on 2016-02-04 for implantable device for the delivery of risperidone and methods of use thereof.
This patent application is currently assigned to BRAEBURN PHARMACEUTICALS BVBA SPRL. The applicant listed for this patent is BRAEBURN PHARMACEUTICALS BVBA SPRL. Invention is credited to Petr Kuzma, Harry Quandt.
Application Number | 20160030337 14/735588 |
Document ID | / |
Family ID | 41557511 |
Filed Date | 2016-02-04 |
United States Patent
Application |
20160030337 |
Kind Code |
A1 |
Kuzma; Petr ; et
al. |
February 4, 2016 |
IMPLANTABLE DEVICE FOR THE DELIVERY OF RISPERIDONE AND METHODS OF
USE THEREOF
Abstract
This invention is related to the use of polyurethane-based
polymer as a drug delivery device to deliver biologically active
risperidone at a constant rate for an extended period of time and
methods of manufactures thereof. The device is very biocompatible
and biostable, and is useful as an implant in patients (humans and
animals) for the delivery of risperidone to tissues or organs.
Inventors: |
Kuzma; Petr; (Princeton,
NJ) ; Quandt; Harry; (Bensalem, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
BRAEBURN PHARMACEUTICALS BVBA SPRL |
Brussels |
|
BE |
|
|
Assignee: |
BRAEBURN PHARMACEUTICALS BVBA
SPRL
Brussels
BE
|
Family ID: |
41557511 |
Appl. No.: |
14/735588 |
Filed: |
June 10, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12569558 |
Sep 29, 2009 |
9078900 |
|
|
14735588 |
|
|
|
|
61117448 |
Nov 24, 2008 |
|
|
|
61101548 |
Sep 30, 2008 |
|
|
|
Current U.S.
Class: |
424/423 ;
514/259.41 |
Current CPC
Class: |
A61K 31/519 20130101;
A61P 25/18 20180101; A61K 9/0024 20130101; A61K 9/0092 20130101;
A61P 25/24 20180101; A61P 25/00 20180101; A61K 47/34 20130101 |
International
Class: |
A61K 9/00 20060101
A61K009/00; A61K 47/34 20060101 A61K047/34; A61K 31/519 20060101
A61K031/519 |
Claims
1.-25. (canceled)
26. A drug delivery device for the controlled release of
risperidone over an extended period of time to produce systemic
pharmacological effects, comprising: a) a polyurethane-based
polymer formed to define a hollow space; and b) a solid drug
formulation consisting essentially of a formulation consisting
essentially of risperidone and optionally one or more
pharmaceutically acceptable carriers, wherein the solid drug
formulation is contained in the hollow space, and wherein the
device provides a pre-determined release rate of risperidone from
the device after implantation, and wherein the polyurethane-based
polymer is a reaction product of 4,4'-diisocyanato
dicyclohexylmethane (H12MDI), polytetramethylene ether glycol
(PTMEG) and 1,4-butanediol.
27. The drug delivery device of claim 26, wherein the drug delivery
device is conditioned and primed under conditions chosen to be
consistent with the water solubility characteristics of the
risperidone.
28. The drug delivery device of claim 26 including one or more
pharmaceutically acceptable carriers, and wherein the
pharmaceutically acceptable carrier is stearic acid.
29. The drug delivery device of claim 28, wherein the stearic acid
comprises about 2 wt % of the solid drug formulation.
30. The drug delivery device of claim 26, wherein the
polyurethane-based polymer has a flex modulus of between about 1000
and about 92,000 psi.
31. The drug delivery device of claim 26, which has an internal
diameter of about 3.6 mm.
32. The drug delivery device of claim 26, which has a length of
about 7.5 mm to about 50 mm.
33. The drug delivery device of claim 26, which has a length of
about 45 mm.
34. The drug delivery device of claim 26, wherein the
polyurethane-based polymer has a wall thickness of 0.2 mm.
35. The drug delivery device of claim 26, wherein the device
provides a pre-determined release rate of risperidone of between
about 0.001 mg/day to about 15 mg/day from the device after
implantation.
36. A method for delivering an effective amount of risperidone to a
subject, comprising implanting the drug delivery device of claim 26
into the subject.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 61/101,548 filed Sep. 30, 2008, and U.S.
Provisional Application No. 61/117,448 filed Nov. 24, 2008, the
entire disclosures of which are incorporated herein by
reference.
BACKGROUND
[0002] Due to its excellent biocompatibility, biostability and
physical properties, polyurethane or polyurethane-containing
polymers have been used to fabricate a large number of implantable
devices, including pacemaker leads, artificial hearts, heart
valves, stent coverings, artificial tendons, arteries and veins.
Formulations for delivery of active agents using polyurethane
implantable devices, however, require a liquid medium or carrier
for the diffusion of the drug at a zero order rate.
SUMMARY
[0003] Described herein are methods and compositions based on the
unexpected discovery that solid formulations comprising one or more
active agents can be used at the core of a polyurethane implantable
device such that the active agent is released in a
controlled-release, zero-order manner from the implantable device.
The active agents and polyurethane coating can be selected based on
various physical parameters, and then the release rate of the
active from the implantable device can be optimized to a clinically
relevant release rate based on clinical and/or in vitro trials.
[0004] One embodiment is directed to a method for delivering a
formulation comprising an effective amount of risperidone to a
subject, comprising: implanting an implantable device into the
subject, wherein the implantable device comprises risperidone or a
formulation thereof substantially surrounded by a
polyurethane-based polymer. In a particular embodiment, the
polyurethane-based polymer is formed from one or more polyols,
wherein the general polyol structure is selected from the group
consisting of
[O--(CH.sub.2).sub.n].sub.x--O--;
O--(CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2).sub.x--O--; and
O--[(CH.sub.2).sub.6--CO.sub.3].sub.n--(CH.sub.2)--O--
[0005] For the compositions and methods described herein, the
values for n and x are integer values of between about 1 and about
1,000,000; of between about 2 and about 500,000; of between about 5
and about 250,000; and of between about 10 and about 100,000. In a
particular embodiment, the polyol comprises
--[O--(CH.sub.2).sub.n].sub.x--O--, wherein the polyurethane-based
polymer has an equilibrium water content of between about 5% and
about 200%, e.g., of at least about 15%. In a particular
embodiment, risperidone is released at a zero-order rate of about
149 .mu.g/day per square centimeter of the surface area of the
implantable device. In a particular embodiment, the polyol
comprises O--(CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2).sub.x--O--,
wherein the polyurethane-base polymer has a flex modulus of between
about 1000 and about 92,000 psi, e.g., of about 2,300 psi. In a
particular embodiment, risperidone is released at a zero-order rate
of about 146 .mu.g/day per square centimeter of the surface area of
the implantable device. In a particular embodiment, the polyol
comprises O--[(CH.sub.2).sub.6--CO.sub.3].sub.n--(CH.sub.2)--O--,
wherein the polyurethane-based polymer has a flex modulus of
between about 620 and about 92,000 psi, e.g., of about 620 psi. In
a particular embodiment, risperidone is released at a zero-order
rate of about 40 .mu.g/day per square centimeter of the surface
area of the implantable device.
[0006] One embodiment is directed to a drug delivery device for the
controlled release of risperidone over an extended period of time
to produce local or systemic pharmacological effects, comprising:
a) a polyurethane-based polymer formed to define a hollow space;
and b) a solid drug formulation comprising a formulation comprising
risperidone and optionally one or more pharmaceutically acceptable
carriers, wherein the solid drug formulation is contained in the
hollow space, and wherein the device provides a desired release
rate of risperidone from the device after implantation. In a
particular embodiment, the drug delivery device is conditioned and
primed under conditions chosen to be consistent with the water
solubility characteristics of the at least one active agent. In a
particular embodiment, the pharmaceutically acceptable carrier is
stearic acid. In a particular embodiment, the polyurethane-based
polymer is formed from one or more polyols, wherein the general
polyol structure is selected from the group consisting of:
--[O--(CH.sub.2).sub.n].sub.x--O--;
O--(CH.sub.2--CH.sub.2--CH.sub.2--(CH.sub.2).sub.x--O--; and
O--[(CH.sub.2).sub.6--CO.sub.3].sub.n--(CH.sub.2)--O--
[0007] In a particular embodiment, the polyol comprises
--[O--(CH.sub.2).sub.n].sub.x--O--, wherein the polyurethane-based
polymer has an equilibrium water content of between about 5% and
about 43%, e.g., of at least about 15%. In a particular embodiment,
risperidone is released at a zero-order rate of about 149 .mu.g/day
per square centimeter of the surface area of the implantable
device. In a particular embodiment, the polyol comprises
O--(CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2, wherein the
polyurethane-base polymer has a flex modulus of between about 1000
and about 92,000 psi, e.g., of about 2,300 psi. In a particular
embodiment, risperidone is released at a zero-order rate of about
146 .mu.g/day per square centimeter of the surface area of the
implantable device. In a particular embodiment, the polyol
comprises O--[(CH.sub.2).sub.6--CO.sub.3].sub.n--(CH.sub.2)--O--,
wherein the polyurethane-based polymer has a flex modulus of
between about 620 and about 92,000 psi, e.g., of about 620 psi. In
a particular embodiment, risperidone is released at a zero-order
rate of about 40 .mu.g/day per square centimeter of the surface
area of the implantable device. In a particular embodiment,
appropriate conditioning and priming parameters can be selected to
establish the desired delivery rates of the at least one active
agent, wherein the priming parameters are time, temperature,
conditioning medium and priming medium.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] FIG. 1 is a side view of an implant with two open ends.
[0009] FIG. 2 is a side view of pre-fabricated end plugs used to
plug the implants.
[0010] FIG. 3 is a side view of an implant with one open end.
[0011] FIG. 4 is a graph of the release rate of risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (Flex Modulus 620
psi) prepared from tubing sections representing the beginning,
middle and end of a coil of tubing as part of an assessment of the
uniformity of the material within a particular lot. Samples were
evaluated weekly for one year. All implants were of equivalent
geometry and drug load.
[0012] FIG. 5 is a graph of the release rate of risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (Flex Modulus 620
psi) as part of an assessment of the effect using saline versus
aqueous hydroxypropyl betacellulose solution (15% in phosphate
buffered saline) as the elution media. Samples were evaluated
weekly for 11 weeks. All implants were of equivalent geometry and
drug load.
[0013] FIGS. 6A and 6B are graphs comparing the release rates of
risperidone from Carbothane.RTM. PC-3595A polyurethane implants
(Flex modulus 4500 psi) to Tecophilic.RTM. HP-60D-20 polyurethane
implants (EWC, 14.9%) as part of the evaluation of the release of
the active from either hydrophilic and hydrophobic polyurethane
materials. Samples were evaluated weekly for 22 weeks for the
Carbothane.RTM. implant. Samples were evaluated weekly for 15 weeks
for the Tecophilic.RTM. implant. All implants were of equivalent
geometry and drug load. FIG. 11B is a graph of the release rate of
risperidone from Tecophilic.RTM. HP-60D-20 polyurethane implants
(EWC, 14.9%) alone, sampled weekly for 15 weeks.
[0014] FIG. 7 is a graph comparing the release rates of risperidone
from Tecoflex.RTM. EG-80A polyurethane implants (Flex Modulus 1000
psi) and two grades of Tecophilic.RTM. polyurethane implants,
HP-60D-35 and HP-60D-60 (EWC, 23.6% and 30.8%, respectively). All
were sampled weekly for 10 weeks. All implants were of equivalent
geometry and drug load.
[0015] FIG. 8 is a graph of the release rate of risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (Flex Modulus 620
psi) that served as in vitro controls for implants used in the
beagle dog study described in Example 8. The in vitro elution study
of these implants was initiated on the date of implantation of the
subject implants as part of an assessment of in vivo-in vitro
correlation.
[0016] FIG. 9 is a graph of the in vivo plasma concentration of
risperidone in the beagle dog study described in Example 8. The
lower plot represents the average plasma concentration achieved in
dogs implanted with one Carbothane.RTM. PC-3575A polyurethane
implant (Flex Modulus 620 psi). The upper plot represents the
average plasma concentration achieved in dogs implanted with two
Carbothane.RTM. PC-3575A polyurethane implants (Flex Modulus 620
psi).
[0017] FIG. 10 is a graph showing the in vitro release of
risperidone from Tecoflex.RTM. and Carbothane.RTM. implants. The
pellets comprising the risperidone formulation had a diameter of
3.5 mm, a length of about 4.5 mm and a weight of 5.4 mg. The
implant had a reservoir length of about 39-40 mm, a wall thickness
of 0.2 mm, and internal diameter of 3.6 mm and an overall length of
about 45 mm.
[0018] FIG. 11 is a graph showing the in vivo release of
risperidone from Tecoflex.RTM. and Carbothane.RTM. implants, as
compared to a control. The pellets comprising the risperidone
formulation had a diameter of 3.5 mm, a length of about 4.5 mm and
a weight of 5.4 mg. The implant had a reservoir length of about
39-40 mm, a wall thickness of 0.2 mm, and internal diameter of 3.6
mm and an overall length of about 45 mm.
DETAILED DESCRIPTION
[0019] To take the advantage of the excellent properties of
polyurethane-based polymers, the present invention is directed to
the use of polyurethane-based polymers as drug delivery devices for
releasing drugs at controlled rates for an extended period of time
to produce local or systemic pharmacological effects. The drug
delivery device can comprise a cylindrically shaped reservoir
surrounded by polyurethane-based polymer that controls the delivery
rate of the drug inside the reservoir. The reservoir contains a
formulation, e.g., a solid formulation, comprising one or more
active ingredients and, optionally, pharmaceutically acceptable
carriers. The carriers are fog ululated to facilitate the diffusion
of the active ingredients through the polymer and to ensure the
stability of the drugs inside the reservoir.
[0020] A polyurethane is any polymer consisting of a chain of
organic units joined by urethane links. Polyurethane polymers are
formed by reacting a monomer containing at least two isocyanate
functional groups with another monomer containing at least two
alcohol groups in the presence of a catalyst. Polyurethane
formulations cover a wide range of stiffness, hardness, and
densities.
##STR00001##
[0021] Polyurethanes are in the class of compounds called "reaction
polymers," which include epoxies, unsaturated polyesters and
phenolics. A urethane linkage is produced by reacting an isocyanate
group, --N.dbd.C.dbd.O with a hydroxyl (alcohol) group, --OH.
Polyurethanes are produced by the polyaddition reaction of a
polyisocyanate with a polyalcohol (polyol) in the presence of a
catalyst and other additives. In this case, a polyisocyanate is a
molecule with two or more isocyanate functional groups,
R--(N.dbd.C.dbd.O).sub.n.gtoreq.2 and a polyol is a molecule with
two or more hydroxyl functional groups, R'--(OH).sub.n.gtoreq.2.
The reaction product is a polymer containing the urethane linkage,
--RNHCOOR'--. Isocyanates react with any molecule that contains an
active hydrogen. Importantly, isocyanates react with water to form
a urea linkage and carbon dioxide gas; they also react with
polyetheramines to form polyureas.
[0022] Polyurethanes are produced commercially by reacting a liquid
isocyanate with a liquid blend of polyols, catalyst, and other
additives. These two components are referred to as a polyurethane
system, or simply a system. The isocyanate is commonly referred to
in North America as the "A-side" or just the "iso," and represents
the rigid backbone (or "hard segment") of the system. The blend of
polyols and other additives is commonly referred to as the "B-side"
or as the "poly," and represents the functional section (or "soft
segment") of the system. This mixture might also be called a
"resin" or "resin blend." Resin blend additives can include chain
extenders, cross linkers, surfactants, flame retardants, blowing
agents, pigments and fillers. In drug delivery applications, the
"soft segments" represent the section of the polymer that imparts
the characteristics that determine the diffusivity of an active
pharmaceutical ingredient (API) through that polymer.
[0023] The elastomeric properties of these materials are derived
from the phase separation of the hard and soft copolymer segments
of the polymer, such that the urethane hard segment domains serve
as cross-links between the amorphous polyether (or polyester) soft
segment domains. This phase separation occurs because the mainly
non-polar, low-melting soft segments are incompatible with the
polar, high-melting hard segments. The soft segments, which are
formed from high molecular weight polyols, are mobile and are
normally present in coiled formation, while the hard segments,
which are formed from the isocyanate and chain extenders, are stiff
and immobile. Because the hard segments are covalently coupled to
the soft segments, they inhibit plastic flow of the polymer chains,
thus creating elastomeric resiliency. Upon mechanical deformation,
a portion of the soft segments are stressed by uncoiling, and the
hard segments become aligned in the stress direction. This
reorientation of the hard segments and consequent powerful
hydrogen-bonding contributes to high tensile strength, elongation,
and tear resistance values.
[0024] The polymerization reaction is catalyzed by tertiary amines,
such as, for example, dimethylcyclohexylamine, and organometallic
compounds, such as, for example, dibutyltin dilaurate or bismuth
octanoate. Furthermore, catalysts can be chosen based on whether
they favor the urethane (gel) reaction, such as, for example,
1,4-diazabicyclo[2.2.2]octane (also called DABCO or TEDA), or the
urea (blow) reaction, such as bis-(2-dimethylaminoethyl)ether, or
specifically drive the isocyanate trimerization reaction, such as
potassium octoate.
##STR00002##
[0025] Isocyanates with two or more functional groups are required
for the formation of polyurethane polymers. Volume wise, aromatic
isocyanates account for the vast majority of global diisocyanate
production. Aliphatic and cycloaliphatic isocyanates are also
important building blocks for polyurethane materials, but in much
smaller volumes. There are a number of reasons for this. First, the
aromatically-linked isocyanate group is much more reactive than the
aliphatic one. Second, aromatic isocyanates are more economical to
use. Aliphatic isocyanates are used only if special properties are
required for the final product. Light stable coatings and
elastomers, for example, can only be obtained with aliphatic
isocyanates. Aliphatic isocyanates also are favored in the
production of polyurethane biomaterials due to their inherent
stability and elastic properties.
[0026] Examples of aliphatic and cycloaliphatic isocyanates
include, for example, 1,6-hexamethylene diisocyanate (HDI),
1-isocyanato-3-isocyanatomethyl-3,5,5-trimethyl-cyclohexane
(isophorone diisocyanate, IPDI), and 4,4'-di isocyanato
dicyclohexylmethane (H12MDI). They are used to produce light
stable, non-yellowing polyurethane coatings and elastomers. H12MDI
prepolymers are used to produce high performance coatings and
elastomers with optical clarity and hydrolysis resistance.
Tecoflex.RTM., Tecophilic.RTM. and Carbothane.RTM. polyurethanes
are all produced from H12MDI prepolymers.
[0027] Polyols are higher molecular weight materials manufactured
from an initiator and monomeric building blocks, and, where
incorporated into polyurethane systems, represent the "soft
segments" of the polymer. They are most easily classified as
polyether polyols, which are made by the reaction of epoxides
(oxiranes) with an active hydrogen containing starter compounds, or
polyester polyols, which are made by the polycondensation of
multifunctional carboxylic acids and hydroxyl compounds.
[0028] Tecoflex.RTM. polyurethanes, Tecogel.RTM. polyurethanes and
Tecophilic.RTM. polyurethanes are cycloaliphatic polymers and are
of the types produced from polyether-based polyols. For the
Tecoflex.RTM. polyurethanes, the general structure of the polyol
segment is represented as,
O--(CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2).sub.x--O--
whereby an increase in "x" represents a increase in flexibility
(decreased "Flex Modulus"; "FM"), yielding FM ranging from about
1000-92,000 psi. From the standpoint of drug release from these
materials, the release of a relatively hydrophobic API decreases as
the FM increases. For the compositions and methods described
herein, the values for x are integer values of between about 1 and
about 1,000,000; of between about 2 and about 500,000; of between
about 5 and about 250,000; and of between about 10 and about
100,000. In still other embodiments, x may range from about 2-500,
about 2-100, about 5-50, and 10-30.
[0029] For the Tecophilic.RTM. (hydrophilic) or Tecogel.RTM.
polyurethanes, the general structure of the polyol segment is
represented as,
--[O--(CH.sub.2).sub.n].sub.x--O--
[0030] whereby increases in "n" and "x" represent variations in
hydrophilicity, and yield equilibrium water contents (% EWC)
ranging from about 5%-200%. For the compositions and methods
described herein, the values for n and x are integer values of
between about 1 and about 1,000,000; of between about 2 and about
500,000; of between about 5 and about 250,000; and of between about
10 and about 100,000. In still other embodiments, n and x may have
the same or different values, with those values ranging from about
2-500, about 2-100, about 5-50, and 10-30. From the standpoint of
drug release from these materials, the release of a relatively
hydrophilic API increases as the % EWC increases.
[0031] Specialty polyols include, for example, polycarbonate
polyols, polycaprolactone polyols, polybutadiene polyols, and
polysulfide polyols.
[0032] Carbothane.RTM. polyurethanes are cycloaliphatic polymers
and are of the types produced from polycarbonate-based polyols. The
general structure of the polyol segment is represented as,
O--[(CH.sub.2).sub.6--CO.sub.3].sub.n--(CH.sub.2)--O--
whereby an increase in "n" represents a increase in flexibility
(decreased FM), yielding FM ranging from about 620-92,000 psi. For
the compositions and methods described herein, the values for n are
integer values of between about 1 and about 1,000,000; of between
about 2 and about 500,000; of between about 5 and about 250,000;
and of between about 10 and about 100,000. In still other
embodiments, n may range from about 2-500, about 2-100, about 5-50,
and 10-30. From the standpoint of drug release from these
materials, the release of a relatively hydrophobic API will
decrease as the FM increases.
[0033] Chain extenders and cross linkers are low molecular weight
hydroxyl- and amine-terminated compounds that play an important
role in the polymer morphology of polyurethane fibers, elastomers,
adhesives and certain integral skin and microcellular foams.
Examples of chain extenders include, for example, ethylene glycol,
1,4-butanediol (1,4-BDO or BDO), 1,6-hexanediol, cyclohexane
dimethanol and hydroquinone bis(2-hydroxyethyl) ether (HQEE). All
of these glycols form polyurethanes that phase separate well, form
well-defined hard segment domains, and are melt processable. They
are all suitable for thermoplastic polyurethanes with the exception
of ethylene glycol, since its derived bis-phenyl urethane undergoes
unfavorable degradation at high hard segment levels.
Tecophilic.RTM., Tecoflex.RTM. and Carbothane.RTM. polyurethanes
all incorporate the use of 1,4-butanediol as the chain
extender.
[0034] The current invention provides a drug delivery device that
can achieve the following objectives: a controlled-release rate
(e.g., zero-order release rate) to maximize therapeutic effects and
minimize unwanted side effects, an easy way to retrieve the device
if it is necessary to end the treatment, an increase in
bioavailability with less variation in absorption and no first pass
metabolism.
[0035] The release rate of the drug is governed by the Fick's Law
of Diffusion as applied to a cylindrically shaped reservoir device
(cartridge). The following equation describes the relationship
between different parameters:
dM dt = 2 .pi. hp .DELTA. C ln ( r o / r i ) ##EQU00001##
[0036] where: [0037] dM/dt: drug release rate; [0038] h: length of
filled portion of device; [0039] .DELTA.C: concentration gradient
across the reservoir wall; [0040] r.sub.o/r.sub.i: ratio of outside
to inside radii of device; and [0041] p: permeability coefficient
of the polymer used.
[0042] The permeability coefficient is primarily regulated by the
hydrophilicity or hydrophobicity of the polymer, the structure of
the polymer, and the interaction of drug and the polymer. Once the
polymer and the active ingredient are selected, p is a constant, h,
ro, and r.sub.i are fixed and kept constant once the cylindrically
shaped device is produced. .DELTA.C is maintained constant.
[0043] To keep the geometry of the device as precise as possible,
the device, e.g., a cylindrically shaped device, can be
manufactured through precision extrusion or precision molding
process for thermoplastic polyurethane polymers, and reaction
injection molding or spin casting process for thermosetting
polyurethane polymers.
[0044] The cartridge can be made with either one end closed or both
ends open. The open end can be plugged with, for example,
pre-manufactured end plug(s) to ensure a smooth end and a solid
seal, or, in the case of thermoplastic polyurethanes, by using
heat-sealing techniques known to those skilled in the art. The
solid actives and carriers can be compressed into pellet form to
maximize the loading of the actives.
[0045] To identify the location of the implant, radiopaque material
can be incorporated into the delivery device by inserting it into
the reservoir or by making it into end plug to be used to seal the
cartridge.
[0046] Once the cartridges are sealed on both ends with the filled
reservoir, they are optionally conditioned and primed for an
appropriate period of time to ensure a constant delivery rate.
[0047] The conditioning of the drug delivery devices involves the
loading of the actives (drug) into the polyurethane-based polymer
that surrounds the reservoir. The priming is done to stop the
loading of the drug into the polyurethane-based polymer and thus
prevent loss of the active before the actual use of the implant.
The conditions used for the conditioning and priming step depend on
the active, the temperature and the medium in which they are
carried out. The conditions for the conditioning and priming may be
the same in some instances.
[0048] The conditioning and priming step in the process of the
preparation of the drug delivery devices is done to obtain a
determined rate of release of a specific drug. The conditioning and
priming step of the implant containing a hydrophilic drug can be
carried out in an aqueous medium, e.g., in a saline solution. The
conditioning and priming step of a drug delivery device comprising
a hydrophobic drug is usually carried out in a hydrophobic medium
such as, for example, an oil-based medium. The conditioning and
priming steps can be carried out by controlling three specific
factors, namely the temperature, the medium and the period of
time.
[0049] A person skilled in the art would understand that the
conditioning and priming step of the drug delivery device is
affected by the medium in which the device is placed. A hydrophilic
drug can be conditioned and primed, for example, in an aqueous
solution, e.g., in a saline solution. The temperature used to
condition and prime the drug delivery device can vary across a wide
range of temperatures, e.g., about 37.degree. C.
[0050] The time period used for the conditioning and priming of the
drug delivery devices can vary from about a single day to several
weeks depending on the release rate desired for the specific
implant or drug. The desired release rate is determined by one of
skill in the art with respect to the particular active agent used
in the pellet formulation.
[0051] A person skilled in the art will understand the steps of
conditioning and priming the implants are to optimize the rate of
release of the drug contained within the implant. As such, a
shorter time period spent on the conditioning and the priming of a
drug delivery device results in a lower rate of release of the drug
compared to a similar drug delivery device that has undergone a
longer conditioning and priming step.
[0052] The temperature in the conditioning and priming step will
also affect the rate of release in that a lower temperature results
in a lower rate of release of the drug contained in the drug
delivery device when compared to a similar drug delivery device
that has undergone a treatment at a higher temperature.
[0053] Similarly, in the case of aqueous solutions, e.g., saline
solutions, the sodium chloride content of the solution determines
what type of rate of release will be obtained for the drug delivery
device. More specifically, a lower content of sodium chloride
results in a higher rate of release of drug when compared to a drug
delivery device that has undergone a conditioning and priming step
where the sodium chloride content was higher.
[0054] The same conditions apply for hydrophobic drugs where the
main difference in the conditioning and priming step is that the
conditioning and priming medium is a hydrophobic medium, more
specifically an oil-based medium.
[0055] The delivery of risperidone can be useful, for example, to
treat schizophrenia, manic states, bipolar disorder, irritability,
autism, obsessive-compulsive disorder, severe treatment-resistant
depression with or without psychotic features, Tourette syndrome,
disruptive behavior disorders in children; and eating disorders.
Risperidone belongs to a class of anti-psychotic drugs known as
"atypical neuroleptics". It is a strong dopamine antagonist. It has
a high affinity for D2 dopaminergic receptors. It has actions at
several 5-HT (serotonin) receptor subtypes. These are 5-HT2C,
linked to weight gain, 5-HT2A, linked to its antipsychotic action
and relief of some of the extrapyramidal side effects experienced
with the "typical neuroleptics" through action at 5-HT1A. The
latter action leads to an increased release of dopamine from
mesocortical neurons in the brain. Effective levels of risperidone
in the blood are known and established and can range, for example,
about 0.1 to about 10 ng/ml, from about 0.5 to about 8 ng/ml or
about 1.0 to about 5 ng/ml range.
[0056] One of skill in the art would be able to tailor risperidone
release by altering a variety of implant factors. For example, as
shown in the Examples, different classes of polyurethanes lead to
different release rates of risperidone. Additionally, within
classes of polyurethanes, the EWC and/or flex modulus of the
polyurethane can be varied to achieve different risperidone release
rates. Further still, one of skill in the art could vary the size
of the implant to increase or decrease the surface area of the
implant, thereby varying the release rate of risperidone from the
implant. Such alterations lead to release rates in the
physiologically-relevant range, e.g., of about 0.001 to about 15
mg/day, from about 0.1 to about 15 mg/day, from about 1 to about
12.5 mg/day, from about 7.5 to about 12.5 mg/day or at about 12.5
mg/day. Release rate from implants can also be varied, for example,
by adjusting the amount and nature of excipients contained in the
risperidone formulation.
[0057] Implants that achieve physiological release rates of
risperidone can vary in size, depending on, for example, the nature
of the polyurethane used. A cylindrical implant, for example, can
have a range of internal diameters from about 1 mm to about 10 mm,
from about 1.5 mm to about 5 mm, from about 1.8 mm to about 3.6 mm,
about 3.6 mm or about 1.8 mm. An implant can range in length from
about, for example, 5 mm to about 100 mm, from about 7.5 mm to
about 50 mm, from about 10 mm to about 40 mm, from about 15 mm to
about 30 mm, about 37 mm, about 40 mm or about 15.24 mm.
[0058] The current invention focuses on the application of
polyurethane-based polymers, thermoplastics or thermosets, to the
creation of implantable drug devices to deliver biologically active
compounds at controlled rates for prolonged period of time.
Polyurethane polymers can be made into, for example, cylindrical
hollow tubes with one or two open ends through extrusion,
(reaction) injection molding, compression molding, or spin-casting
(see e.g., U.S. Pat. Nos. 5,266,325 and 5,292,515), depending on
the type of polyurethane used.
[0059] Thermoplastic polyurethane can be processed through
extrusion, injection molding or compression molding. Thermoset
polyurethane can be processed through reaction injection molding,
compression molding, or spin-casting. The dimensions of the
cylindrical hollow tube should be as precise as possible.
[0060] Polyurethane-based polymers are synthesized from
multi-functional polyols, isocyanates and chain extenders. The
characteristics of each polyurethane can be attributed to its
structure.
[0061] Thermoplastic polyurethanes are made of macrodiols,
diisocyanates, and difunctional chain extenders (e.g., U.S. Pat.
Nos. 4,523,005 and 5,254,662). Macrodiols make up the soft domains.
Diisocyanates and chain extenders make up the hard domains. The
hard domains serve as physical crosslinking sites for the polymers.
Varying the ratio of these two domains can alter the physical
characteristics of the polyurethanes, e.g., the flex modulus.
[0062] Thermoset polyurethanes can be made of multifunctional
(greater than difunctional) polyols and/or isocyanates and/or chain
extenders (e.g., U.S. Pat. Nos. 4,386,039 and 4,131,604). Thermoset
polyurethanes can also be made by introducing unsaturated bonds in
the polymer chains and appropriate crosslinkers and/or initiators
to do the chemical crosslinking (e.g., U.S. Pat. No. 4,751,133). By
controlling the amounts of crosslinking sites and how they are
distributed, the release rates of the actives can be
controlled.
[0063] Different functional groups can be introduced into the
polyurethane polymer chains through the modification of the
backbones of polyols depending on the properties desired. Where the
device is used for the delivery of water soluble drugs, hydrophilic
pendant groups such as ionic, carboxyl, ether, and hydroxyl groups
are incorporated into the polyols to increase the hydrophilicity of
the polymer (e.g., U.S. Pat. Nos. 4,743,673 and 5,354,835). Where
the device is used for the delivery of hydrophobic drugs,
hydrophobic pendant groups such as alkyl, siloxane groups are
incorporated into the polyols to increase the hydrophobicity of the
polymer (e.g., U.S. Pat. No. 6,313,254). The release rates of the
actives can also be controlled by the hydrophilicity/hydrophobicity
of the polyurethane polymers.
[0064] For thermoplastic polyurethanes, precision extrusion and
injection molding are the preferred choices to produce two open-end
hollow tubes (FIG. 1) with consistent physical dimensions. The
reservoir can be loaded freely with appropriate formulations
containing actives and carriers or filled with pre-fabricated
pellets to maximize the loading of the actives. One open end needs
to be sealed first before the loading of the formulation into the
hollow tube. To seal the two open ends, two pre-fabricated end
plugs (FIG. 2) can be used. The sealing step can be accomplished
through the application of heat or solvent or any other means to
seal the ends, preferably permanently.
[0065] For thermoset polyurethanes, precision reaction injection
molding or spin casting is the preferred choice depending on the
curing mechanism. Reaction injection molding is used if the curing
mechanism is carried out through heat and spin casting is used if
the curing mechanism is carried out through light and/or heat.
Hollow tubes with one open end (FIG. 3), for example, can be made
by spin casting. Hollow tubes with two open ends, for example, can
be made by reaction injection molding. The reservoir can be loaded
in the same way as the thermoplastic polyurethanes.
[0066] To seal an open end, an appropriate light-initiated and/or
heat-initiated thermoset polyurethane formulation can be used to
fill the open end, and this is cured with light and/or heat. A
pre-fabricated end plug, for example, can also be used to seal the
open end by applying an appropriate light-initiated and/or
heat-initiated thermoset polyurethane formulation on to the
interface between the pre-fabricated end plug and the open end, and
curing it with the light and/or heat or any other means to seal the
ends, preferably permanently.
[0067] The final process involves the conditioning and priming of
the implants to achieve the delivery rates required for the
actives. Depending upon the types of active ingredient, hydrophilic
or hydrophobic, the appropriate conditioning and priming media is
chosen. Water-based media are preferred for hydrophilic actives,
and oil-based media are preferred for hydrophobic actives.
[0068] As a person skilled in the art would readily know many
changes can be made to the preferred embodiments of the invention
without departing from the scope thereof. It is intended that all
matter contained herein be considered illustrative of the invention
and not it a limiting sense.
EXEMPLIFICATION
Example 1
[0069] Tecophilic.RTM. polyurethane polymer tubes are supplied by
Thermedics Polymer Products and manufactured through a precision
extrusion process. Tecophilic.RTM. polyurethane is a family of
aliphatic polyether-based thermoplastic polyurethane that can be
formulated to different equilibrium water contents (EWC) of up to
150% of the weight of dry resin. Extrusion grade formulations are
designed to provide maximum physical properties of thermoformed
tubing or other components. An exemplary tube and end cap
structures are depicted in FIGS. 1-3.
[0070] The physical data for the polymers is provided below as made
available by Thermedics Polymer Product (tests conducted as
outlined by American Society for Testing and. Materials (ASTM),
Table 1).
TABLE-US-00001 TABLE 1 Tecophilic .RTM. Typical Physical Test Data
ASTM HP-60D-20 HP-60D-35 HP-60D-60 HP-93A-100 Durometer D2240 43D
42D 41D 83A (Shore Hardness) Spec Gravity D792 1.12 1.12 1.15 1.13
Flex Modulus (psi) D790 4,300 4,000 4,000 2,900 Ultimate Tensile
Dry (psi) D412 8,900 7,800 8,300 2,200 Ultimate Tensile Wet (psi)
D412 5,100 4,900 3,100 1,400 Elongation Dry (%) D412 430 450 500
1,040 Elongation Wet (%) D412 390 390 300 620
Example 2
[0071] Tables 2A-C show release rates of risperidone from three
different classes of polyurethane compounds (Tecophilic.RTM.,
Tecoflex.RTM. and Carbothane.RTM.). The release rates have been
normalized to surface area of the implant, thereby adjusting for
slight differences in the size of the various implantable devices.
Risperidone is considered to be hydrophobic (not very
water-soluble), as indicated by the Log P value; for the purposes
of the data provided, a Log P value of greater than about 2.0 is
considered to be not readily soluble in aqueous solution. The
polyurethanes were selected to have varying affinities for water
soluble active agents and varying flexibility (as indicated by the
variation in flex modulus).
[0072] For applications of the polyurethanes useful for the devices
and methods described herein, the polyurethane exhibits physical
properties suitable for the risperidone formulation to be
delivered. Polyurethanes are available or can be prepared, for
example, with a range of EWCs or flex moduli (Table 2). Tables 2A-C
show normalized release rates for various active ingredients from
polyurethane compounds. Tables 2D-F show the non-normalized release
rates for the same active ingredients, together with implant
composition.
TABLE-US-00002 TABLE 2A Polyurethane Type Tecophilic Polyurethane
Grade HP-60D-60 HP-60D-35 HP-60D-20 HP-60D-10 HP-60D-05 Relative
Water % EWC/Flex Modulus Active Solubility 31% EWC 24% EWC 15% EWC
8.7% EWC 5.5% EWC Risperidone Log P = 3.28 -- -- 149
.mu.g/day/cm.sup.2 -- -- (M.W. 410) 10% CC, 2% SA, 28.5 mg API
TABLE-US-00003 TABLE 2B Polyurethane Type Tecoflex Polyurethane
Grade EG-85A EG 100A EG-65D % EWC/Flex Modulus F.M.: 2,300 F.M.:
10,000 F.M.: 37,000 Active Relative Water Solubility Risperidone
Log P = 3.28 146 7.6 1.9 (M.W. 410) .mu.g/day/cm.sup.2
.mu.g/day/cm.sup.2 .mu.g/day/cm.sup.2 10% CC, 2% SA, 10% CC, 2% SA,
10% CC, 2% SA, 27.9 mg API 29.8 mg API 29.7 mg API
TABLE-US-00004 TABLE 2C Polyurethane Type Carbothane Polyurethane
Grade PC-3575A PC-3595A % EWC/Flex Modulus F.M.: 620 F.M.: 4,500
Active Relative Water Solubility Risperidone Log P = 3.28 40 11
(M.W. 410) .mu.g/day/cm.sup.2 .mu.g/day/cm.sup.2 10% CC, 10% CC, 2%
SA, 2% SA, 27.8 mg API 29.7 mg API
TABLE-US-00005 TABLE 2D Polyurethane Tecophilic Grade HP-60D-60
HP-60D-35 HP-60D-20 HP-60D-10 HP-60D-05 Relative Water % EWC Active
Solubility 31% EWC 24% EWC 15% EWC 8.7% EWC 5.5% EWC Risperidone
Log P = 3.28 -- -- 150 .mu.g/day -- -- (M.W. 410) ID: 1.80 mm Wall:
0.30 mm L: 15.24 mm 1.005 cm.sup.2
TABLE-US-00006 TABLE 2E Polyurethane Type Tecoflex Polyurethane
Grade EG-85A EG 100A EG-65D Flex Modulus F.M.: 2,300 F.M.: 10,000
F.M.: 37,000 Active Relative Water Solubility Risperidone Log P =
3.28 150 .mu.g/day 8 .mu.g/day 2 .mu.g/day (M.W. 410) ID: 1.85 mm
ID: 1.85 mm ID: 1.85 mm Wall: 0.20 mm Wall: 0.20 mm Wall: 0.20 mm
L: 16.0 mm L: 16.4 mm L: 16.2 mm 1.030 cm.sup.2 1.056 cm.sup.2
1.043 cm.sup.2
TABLE-US-00007 TABLE 2F Polyurethane Type Carbothane Polyurethane
Grade PC-3575A PC-3595A Flex Modulus F.M.: 620 F.M.: 4,500 Active
Relative Water Solubility Risperidone Log P = 3.28 40 .mu.g/day 11
.mu.g/day (M.W. 410) ID: 1.85 mm ID: 1.85 mm Wall: 0.20 mm Wall:
0.20 mm L: 15.6 mm L: 16.2 mm 1.004 cm.sup.2 1.043 cm.sup.2
[0073] The solubility of an active agent in an aqueous environment
can be measured and predicted based on its partition coefficient
(defined as the ratio of concentration of compound in aqueous phase
to the concentration in an immiscible solvent). The partition
coefficient (P) is a measure of how well a substance partitions
between a lipid (oil) and water. The measure of solubility based on
P is often given as Log P. In general, solubility is determined by
Log P and melting point (which is affected by the size and
structure of the compounds). Typically, the lower the Log P value,
the more soluble the compound is in water. It is possible, however,
to have compounds with high Log P values that are still soluble on
account of, for example, their low melting point. It is similarly
possible to have a low Log P compound with a high melting point,
which is very insoluble.
[0074] The flex modulus for a given polyurethane is the ratio of
stress to strain. It is a measure of the "stiffness" of a compound.
This stiffness is typically expressed in Pascals (Pa) or as pounds
per square inch (psi).
[0075] The elution rate of an active agent from a polyurethane
compound can vary on a variety of factors including, for example,
the relative hydrophobicity/hydrophilicity of the polyurethane (as
indicated, for example, by log P), the relative "stiffness" of the
polyurethane (as indicated, for example, by the flex modulus),
and/or the molecular weight of the active agent to be released.
Example 3. Elution of risperidone from polyurethane implantable
devices
[0076] FIGS. 5-10 are graphs showing elution profiles of
risperidone from various implantable devices over varying periods
of time.
[0077] Release rates were obtained for risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (F.M. 620 psi)
prepared from tubing sections representing the beginning, middle
and end of a coil of tubing as part of an assessment of the
uniformity of the material within a particular lot (FIG. 5).
Samples were evaluated weekly for one year. All implants were of
equivalent geometry and drug load.
[0078] Release rates were obtained for risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (F.M. 620 psi) as
part of an assessment of the effect using saline versus aqueous
hydroxypropyl betacellulose solution (15% in phosphate buffered
saline) as the elution media (FIG. 6). Samples were evaluated
weekly for 11 weeks. All implants were of equivalent geometry and
drug load.
[0079] Release rates were compared for risperidone from
Carbothane.RTM. PC-3595A polyurethane implants (F.M. 4500 psi) and
Tecophilic.RTM. HP-60D-20 polyurethane implants (EWC 14.9%) as part
of the evaluation of the release of the active from either
hydrophilic and hydrophobic polyurethane materials (FIGS. 7A and
7B). Samples were evaluated weekly for 22 weeks for the
Carbothane.RTM. implant. Samples were evaluated weekly for 15 weeks
for the Tecophilic.RTM. implant. All implants were of equivalent
geometry and drug load.
[0080] Release rates were compared for risperidone from
Tecoflex.RTM. EG-80A polyurethane implants (F.M. 1000 psi) and two
grades of Tecophilic.RTM. polyurethane implants, HP-60D-35 and
HP-60D-60 (EWC, 23.6% and 30.8%, respectively) (FIG. 8). All were
sampled weekly for 10 weeks. All implants were of equivalent
geometry and drug load.
[0081] Release rates were obtained for risperidone from
Carbothane.RTM. PC-3575A polyurethane implants (F.M. 620 psi) that
served as in vitro controls for implants used in the beagle dog
study described in Example 4. The in vitro elution study of these
implants was initiated on the date of implantation of the subject
implants as part of an assessment of in vivo-in vitro
correlation.
Example 4
Evaluation of Polyurethane Subcutaneous Implant Devices Containing
Risperidone in Beagle Dogs
[0082] This study determines the blood levels of risperidone from
one or two implants and the duration of time the implants release
the drug. Polyurethane-based implantable devices comprising a
pellet comprising risperidone were implanted into beagles to
determine release rates of risperidone in vivo. The results of the
sample analysis are summarized in Table 3 and FIG. 10. Risperidone
is still present at a high level in the dog plasma at the end of
the third month. The study was conducted in accordance with WCFP's
standard operating procedures (SOPs), the protocol, and any
protocol amendments. All procedure were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals (National
Research Center, National Academy Press, Washington, DC, 1996), and
approved by the Institutional Animal Care and Use Committee in
WCFP.
[0083] The implants initially contained about 80 mg of risperidone
and are designed to deliver approximately 130 mcg/day for 3 months.
The test article was stored at between 2-8.degree. C. before
use.
[0084] The animals were as follows:
[0085] Species: Canine
[0086] Strain: Beagle dog
[0087] Source: Guangzhou Pharm. Industril Research Institute,
[0088] Certification No: SCXK(YUE)2003-0007
[0089] Age at Initiation of Treatment: 6-9 months
[0090] Weight: 8-10 kg
[0091] Number and Sex: 6 males
[0092] Prior to study initiation, animals were assigned a
pretreatment identification number. All animals were weighed before
administration once weekly, and received cage-side observations
daily by qualified veterinarian during acclimation period. All
animals were given a clinical examination prior to selection for
study. Animals with any evidence of disease or physical
abnormalities were not selected for study. The blood sampling was
taken as Baseline at the 3rd and 2nd day before implant. Animals
were then randomized into to 2 groups, with the dosing schedule
provided as follows:
TABLE-US-00008 No. of Animals Dose rate Group Dose Route Male
(mcg/day) Total Dose (mg) 1 Subcutaneous 3 130 23 (single implant
implant) 2 Subcutaneous 3 260 46 (double implant implants)
[0093] Each animal was anesthetized by general anesthesia via
pentobarbital sodium at the dose of 30 mg/kg for device
implantation. The drug was released at a steady rate for several
months. Half the animals received one implant (group 1) and the
others received two implants (group 2). A 5 cm2 area of the
shoulder was shaved and 2 mL of marcaine infused under the skin to
numb the area. A small incision was made on the shoulder and the
device was slid under the skin. The small incision was closed and
the animal was allowed to recover and return to his run. Over the
next five to seven days, the implantation site was be monitored for
signs of infection or reaction. The skin staples were removed when
the skin has healed sufficiently. At the end of three months, the
devices were removed, just as they would clinically.
[0094] Animals were fasted at least four hours prior to blood
sampling. Since blood sampling was done in the morning, food was
withheld overnight. Blood samples were drawn using a 20G needle and
collected directly into the 5 mL tubes containing sodium heparin
and maintained chilled until centrifugation. Samples were then
centrifuged at 5000 RPM for 5 minutes at 4.degree. C. The separated
plasma was then be transferred into two 3 mL cryo tubes. The
samples were labeled with the actual date the sample was taken, the
corresponding study day, the dog identification and the duplicate
sample designator (either A or B). Samples were kept at -20.degree.
C. until ready for analysis.
[0095] On two consecutive days, prior to implantation of the
delivery device, baseline blood samples were taken. In addition,
daily blood samples were taken during the first week and weekly
blood samples were taken for the three months following
implantation. Two 5 mL blood samples were drawn at each time from
each dog. Blood samples were drawn from the cephalic veins
primarily; with the saphenous or jugular used as a backup. For both
the single and double implant groups, blood samples were drawn at
appropriate times as outlined in Table 3 below. Analysis required
at least 2 mL of plasma, which required no less than 10 mL of blood
drawn for each sample. Analysis of plasma concentrations of
risperidone was performed using an LC/MS assay developed for this
compound. A single assay was be run for each sample. Samples were
collected, held at the appropriate condition and analyzed in
batches.
TABLE-US-00009 TABLE 3 Concentration of Risperidone in Dog Plasma
Group 1(single implant) Group 2(double implants) Group 1 Group 2
Date Week Day 1M01 1M02 1M03 2M01 2M02 2M03 Mean S.D. Mean S.D. -3
-- -- -- -- -- -- -2 -- -- -- -- -- -- 1.29 1 1 BLQ BLQ 0.26 BLQ
0.54 BLQ 0.26 / 0.54 / 1.30 1 2 0.77 BLQ 0.24 0.53 1.86 0.46 0.51
0.37 0.95 0.79 1.31 1 3 1.16 0.78 0.37 1.15 2.70 0.92 0.77 0.40
1.59 0.97 2.01 1 4 1.26 0.79 0.66 1.21 3.85 0.94 0.90 0.32 2.00
1.61 2.02 1 5 1.15 0.66 1.03 1.02 3.13 0.77 0.95 0.26 1.64 1.30
2.03 1 6 1.14 0.58 0.52 0.97 2.96 0.79 0.75 0.34 1.57 1.20 2.04 1 7
1.17 0.72 0.44 0.89 3.27 0.73 0.78 0.37 1.63 1.42 2.11 2 14 1.26
1.03 0.38 1.15 2.81 1.01 0.89 0.46 1.66 1.00 2.18 3 21 1.09 0.70
0.62 1.38 3.09 0.91 0.80 0.25 1.79 1.15 2.25 4 28 1.34 0.84 1.02
1.71 3.55 1.10 1.07 0.25 2.12 1.28 3.03 5 35 2.07 2.23 1.65 1.97
4.54 1.12 1.98 0.30 2.54 1.78 3.10 6 42 1.53 1.13 1.87 1.86 3.34
1.40 1.51 0.37 2.20 1.01 3.17 7 49 1.33 1.09 1.16 1.67 2.23 1.29
1.19 0.12 1.73 0.47 3.24 8 56 1.56 1.29 1.30 1.28 2.09 1.54 1.38
0.15 1.64 0.41 3.31 9 63 1.06 0.83 1.39 1.13 2.27 0.97 1.09 0.28
1.46 0.71 4.07 10 70 1.39 1.00 1.36 1.42 3.51 1.48 1.25 0.22 2.14
1.19 4.14 11 77 1.23 1.15 1.41 1.61 3.47 1.07 1.26 0.13 2.05 1.26
4.21 12 84 1.29 1.10 1.21 1.23 3.47 1.23 1.20 0.10 1.98 1.29 4.28
13 91 1.38 0.88 1.10 1.09 3.22 1.38 1.12 0.25 1.90 1.16 5.05 14 98
1.94 1.01 1.32 1.28 3.76 1.19 1.42 0.47 2.08 1.46 5.12 15 105 1.54
0.98 1.23 1.37 3.48 1.31 1.25 0.28 2.05 1.24 5.19 16 112 1.61 0.94
1.30 1.22 3.98 1.59 1.28 0.34 2.26 1.50 5.26 17 119 1.36 0.97 1.49
1.48 2.66 1.65 1.27 0.27 1.93 0.64 6.02 18 126 1.40 0.93 0.95 0.99
3.25 1.16 1.09 0.27 1.80 1.26 6.09 19 133 1.47 1.19 1.33 1.36 3.36
0.98 1.33 0.14 1.90 1.28 6.16 20 140 1.16 1.25 0.85 3.2* 3.46 1.03
1.09 0.21 2.25 1.72 6.23 21 147 1.16 1.23 1.26 1.17 5.56 1.53 1.22
0.05 2.75 2.44 6.30 22 154 1.63 2.02* 1.44 1.41 5.21 1.34 1.54 0.13
2.65 2.21 7.07 23 161 1.26 1.04 0.92 1.41 44.82** 1.36 1.07 0.17
1.39 0.04 7.14 24 168 1.85 0.9 BLQ 1.5 3.78 1.26 1.38 0.67 2.18
1.39 7.21 25 175 1.69 1 BLQ 1.29 3.46 1.3 1.35 0.49 2.02 1.25 7.28
26 182 1.42 1.09* 0.34 1.7 4.48 1.82 0.88 0.76 2.67 1.57
*re-analysis **re-analysis, abnormal data
[0096] FIG. 9 is a graph of the in vivo plasma concentration of
risperidone in the beagle dog study. The lower plot represents the
average plasma concentration achieved in dogs implanted with one
Carbothane.RTM. PC-3575A polyurethane implant (F.M. 620 psi). The
upper plot represents the average plasma concentration achieved in
dogs implanted with two Carbothane.RTM. PC-3575A polyurethane
implants (F.M. 620 psi).
Example 5
Evaluation of Polyurethane Subcutaneous Implant Devices Containing
Risperidone in Beagle Dogs
[0097] Expanding on the data presented in Example 4, this study
determines the blood levels of risperidone from one or two larger
implants and the duration of time the implants release the drug.
Polyurethane-based implantable devices comprising a pellet
comprising risperidone were implanted into beagles to determine
release rates of risperidone in vivo. The results of the larger
implant data are summarized in FIG. 10 (in vitro elution profile)
and FIG. 11 (elution in beagle dogs).
[0098] The pellets comprising the risperidone formulation used for
this study had a diameter of 3.5 mm, a length of about 4.5 mm and a
weight of 5.4 mg. The implant had a reservoir length of about 39-40
mm, a wall thickness of 0.2 mm, and internal diameter of 3.6 mm and
an overall length of about 45 mm. initially contained about 80 mg
of risperidone and are designed to deliver approximately 130
mcg/day for 3 months.
EQUIVALENTS
[0099] The present disclosure is not to be limited in terms of the
particular embodiments described in this application, which are
intended as illustrations of various aspects. Many modifications
and variations can be made without departing from the spirit and
scope of the disclosure, as will be apparent to those skilled in
the art. Functionally equivalent methods, systems, and apparatus
within the scope of the disclosure, in addition to those enumerated
herein, will be apparent to those skilled in the art from the
foregoing descriptions. Such modifications and variations are
intended to fall within the scope of the appended claims. The
present disclosure is to be limited only by the terms of the
appended claims, along with the full scope of equivalents to which
such claims are entitled. It is to be understood that this
disclosure is not limited to particular methods, reagents,
compounds compositions or biological systems, which can, of course,
vary. It is also to be understood that the terminology used herein
is for the purpose of describing particular embodiments only, and
is not intended to be limiting. As will be understood by one
skilled in the art, for any and all purposes, such as in terms of
providing a written description, all ranges disclosed herein also
encompass any and all possible subranges and combinations of
subranges thereof.
[0100] While various aspects and embodiments have been disclosed
herein, other aspects and embodiments will be apparent to those
skilled in the art. All references cited herein are incorporated by
reference in their entireties.
* * * * *